A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.
The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.
In Q4 Natera tallied revenues of $53.8 million compared to $49.3 million a year ago, falling short of the consensus Wall Street estimate of $57.1 million.
